Boris Bol̈l

Prof. Dr. Boris Bol̈l

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
PKPhilipp Koehler
Philipp Koehler
MBMatteo Bassetti
Matteo Bassetti
ACArunaloke Chakrabarti
Arunaloke Chakrabarti
SCSharon Chen
Sharon Chen
Arnaldo L. ColomboArnaldo L. Colombo
Arnaldo L. Colombo
OCOliver A. Cornely
Oliver A. Cornely

27 April 2020 in Mycoses
Verified
Journal Article
Open access
PDF file
PKPhilipp Koehler
Philipp Koehler
OCOliver A. Cornely
Oliver A. Cornely
Bernd BöttigerBernd Böttiger
Bernd Böttiger
FDFabian Dusse
Fabian Dusse
DEDennis A. Eichenauer
Dennis A. Eichenauer
ASAlexander Shimabukuro-Vornhagen
Alexander Shimabukuro-Vornhagen
Summary: Objectives: Patients with acute respiratory distress syndrome (ARDS) due to viral infection are at risk for secondary complications like invasive aspergillosis. Our study evaluates coronavirus disease 19 (COVID‐19) associated invasive aspergillosis at a single centre in Cologne, Germany.Methods: A retrospective chart review of all patients with COVID‐19 associated ARDS admitted to the medical or surgical intensive care unit at the University Hospital of Cologne, Cologne, Germany.Results: COVID‐19 associated invasive pulmonary aspergillosis was found in five of 19 consecutive critically ill patients with moderate to severe ARDS.Conclusion: Clinicians caring for patients with ARDS due to COVID‐19 should consider invasive pulmonary aspergillosis and subject respiratory samples to comprehensive analysis to detect co‐infection.

30 September 2020 in Annals of Hematology
Verified
Journal Article
Open access
PDF file
BBBoris Bol̈l
Boris Bol̈l
ESEnrico Schalk
Enrico Schalk
DBDieter Buchheidt
Dieter Buchheidt
JHJustin Hasenkamp
Justin Hasenkamp
MKMichael Kiehl
Michael Kiehl
MHMarcus Hentrich
Marcus Hentrich
Cancer patients frequently require central venous catheters for therapy and parenteral nutrition and are at high risk of central venous catheter–related infections (CRIs). Moreover, CRIs prolong hospitalization, cause an excess in resource utilization and treatment cost, often delay anti-cancer treatment, and are associated with a significant increase in mortality in cancer patients. We therefore summoned a panel of experts by the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) and updated our previous guideline on CRIs in cancer patients. After conducting systematic literature searches on PubMed, Medline, and Cochrane databases, video- and meeting-based consensus discussions were held. In the presented guideline, we summarize recommendations on definition, diagnosis, management, and prevention of CRIs in cancer patients including the grading of strength of recommendations and the respective levels of evidence. This guideline supports clinicians and researchers alike in the evidence-based decision-making in the management of CRIs in cancer patients.

18 November 2021 in Journal of Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
JNJan-Hendrik Naendrup
Jan-Hendrik Naendrup
JBJorge Garcia Borrega
Jorge Garcia Borrega
DEDennis Alexander Eichenauer
Dennis Alexander Eichenauer
ASAlexander Shimabukuro-Vornhagen
Alexander Shimabukuro-Vornhagen
MKMatthias Kochanek
Matthias Kochanek
BBBoris Bol̈l
Boris Bol̈l
Reactivation of viruses such as Epstein-Barr virus (EBV) and cytomegalovirus (CMV) are common in critically ill patients and have been described in patients with severe COVID-19. However, it is unclear whether these reactivations are associated with increased mortality and whether targeted treatments are beneficial. In a retrospective single-center cohort study, patients with severe COVID-19 treated on our intensive care unit (ICU) were screened for EBV and CMV reactivation as detected by polymerase chain reaction. If present, patient characteristics, temporal connections to severe acute respiratory syndrome coronavirus 2 diagnosis and corticosteroid use, the use of targeted treatments as well as the course of disease and outcome were analyzed. As control group, non-COVID-19 patients with sepsis, treated within the same time period on our ICU, served as control group to compare incidences of viral reactivation. In 19 (16%) of 117 patients with severe COVID-19 treated on our ICU EBV reactivations were identified, comparable 18 (14%) of 126 in the non-COVID-19 control group (P = .672). Similarly, in 11 (9%) of 117 patients CMV reactivations were identified, comparable to the 16 (13%) of 126 in the non-COVID-19 sepsis patients (P = .296). The majority of EBV (58%) and CMV reactivations (55%) were detected in patients under systemic corticosteroid treatment. 7 (37%) of 19 patients with EBV reactivation survived the ICU stay, 2 (29%) of 7 patients with rituximab treatment and 5 (42%) of 12 patients without treatment (P = .568). Five (50%) of 10 patients with CMV reactivation survived the ICU stay, 5 (83%) of 6 patients with ganciclovir treatment and 0 of 4 patients without treatment (P = .048). Follow-up analysis in these patients showed that the initiation of treatment lead to decrease in viral load. Critically ill patients with COVID-19 are at a high risk for EBV and CMV reactivations. Whether these reactivations are a cause of hyperinflammation and require targeted treatment remains uncertain. However, in patients with clinical deterioration or signs of hyperinflammation targeted treatment might be beneficial and warrants further studying.

7 August 2019 in Journal of Intensive Care
Verified
Journal Article
Open access
PDF file
F(for the Working Party on Intensive Care Medicine in Hematologic and Oncologic Patients (iCHOP) of the German Society of Hematology and Medical Oncology (DGHO)
for the Working Party on Intensive Care Medicine in Hematologic and Oncologic Patients (iCHOP) of the German Society of Hematology and Medical Oncology (DGHO)
LPLucie Probst
Lucie Probst
ESEnrico Schalk
Enrico Schalk
TLTobias Liebregts
Tobias Liebregts
VZVanja Zeremski
Vanja Zeremski
BBBoris Bol̈l
Boris Bol̈l
With Sepsis-3, the increase in sequential organ failure assessment (SOFA) as a clinical score for the identification of patients with sepsis and quickSOFA (qSOFA) for the identification of patients at risk of sepsis outside the intensive care unit (ICU) were introduced in 2016. However, their validity has been questioned, and their applicability in different settings and subgroups, such as hematological cancer patients, remains unclear. We therefore assessed the validity of SOFA, qSOFA, and the systemic inflammatory response syndrome (SIRS) criteria regarding the diagnosis of sepsis and the prediction of in-hospital mortality in a multicenter cohort of hematological cancer patients treated on ICU and non-ICU settings. We retrospectively calculated SIRS, SOFA, and qSOFA scores in our cohort and applied the definition of sepsis as “life-threatening organ dysfunction caused by dysregulated host response to infection” as reference. Discriminatory capacity was assessed using the area under the receiver operating characteristic curve (AUROC). Among 450 patients with hematological cancer (median age 58 years, 274 males [61%]), 180 (40%) had sepsis of which 101 (56%) were treated on ICU. For the diagnosis of sepsis, sensitivity was 86%, 64%, and 42% for SIRS, SOFA, and qSOFA, respectively. However, the AUROCs of SOFA and qSOFA indicated better discrimination for sepsis than SIRS (SOFA, 0.69 [95% CI, 0.64–0.73] p < 0.001; qSOFA, 0.67 [95% CI, 0.62–0.71] p < 0.001; SIRS, 0.57 [95% CI, 0.53–0.61] p < 0.001). In-hospital mortality was 40% and 14% in patients with and without sepsis, respectively (p < 0.001). Regarding patients with sepsis, mortality was similar in patients with positive and negative SIRS scores (39% vs. 40% (p = 0.899), respectively). For patients with qSOFA ≥ 2, mortality was 49% compared to 33% for those with qSOFA < 2 (p = 0.056), and for SOFA 56% vs. 11% (p < 0.001), respectively. SOFA allowed significantly better discrimination for in-hospital mortality (AUROC 0.74 [95% CI, 0.69–0.79] p < 0.001) than qSOFA (AUROC 0.65 [95% CI, 0.60–0.71] p < 0.001) or SIRS (AUROC 0.49 [95% CI, 0.44–0.54] p < 0.001). An increase in SOFA score of ≥ 2 had better prognostic accuracy for both diagnosis of sepsis and in-hospital mortality in this setting, and especially on ICU, we observed limited validity of SIRS criteria and qSOFA in identifying hematological patients with sepsis and at high risk of death.

8 November 2018 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
BBBoris Bol̈l
Boris Bol̈l
HGHelen Görgen
Helen Görgen